Hoth Therapeutics (Hoth Therapeutics) Price-to-Tangible-Book : 0.59 (As of May. 13, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Hoth Therapeutics Price-to-Tangible-Book?

As of today (2024-05-13), Hoth Therapeutics's share price is $1.20. Hoth Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $2.03. Hence, Hoth Therapeutics's Price to Tangible Book Ratio of today is 0.59.

The historical rank and industry rank for Hoth Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

HOTH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.58 Med: 1.98 Max: 26.14
Current: 0.59

During the past 7 years, Hoth Therapeutics's highest Price to Tangible Book Ratio was 26.14. The lowest was 0.58. And the median was 1.98.

HOTH's Price-to-Tangible-Book is ranked better than
92.79% of 1220 companies
in the Biotechnology industry
Industry Median: 2.71 vs HOTH: 0.59

A closely related ratio is called PB Ratio. As of today, Hoth Therapeutics's share price is $1.20. Hoth Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $2.03. Hence, Hoth Therapeutics's P/B Ratio of today is 0.59.

Hoth Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Hoth Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hoth Therapeutics Price-to-Tangible-Book Chart

Hoth Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

26.14

6.86

1.60

1.98

0.71

Hoth Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															1.98	0.57	1.00	0.63	0.71

Competitive Comparison of Hoth Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Hoth Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hoth Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hoth Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Hoth Therapeutics's Price-to-Tangible-Book falls into.

Hoth Therapeutics Price-to-Tangible-Book Calculation

Hoth Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	1.20	/	2.027
	=	0.59

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Hoth Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Hoth Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Hoth Therapeutics (Hoth Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hoth Therapeutics Inc (NAS:HOTH) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Rockefeller Plaza, Suite 1039, New York, NY, USA, 10020

Website

https://www.hoththerapeutics.com

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Executives

Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Robb Knie	director, officer: CEO and President	C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Stefanie Johns	officer: Chief Scientific Officer	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Anthony Hayes	director	1796 SHADY LANE, COLUMBIA SC 29206
Wayne Linsley	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Graig Springer	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Spherix Inc	10 percent owner	725 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Vadim Mats	director	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Rice Kenneth L Jr	director	C/O 85 MAIN STREET, HOPKINTON MA 01748
David Sarnoff	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
David S. Briones	officer: Chief Financial Officer	C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Matthew D. Eitner	10 percent owner	44 BRAMS HILL DRIVE, MAHWAH NJ 07430
Kevin Jess Poor	10 percent owner	750 BEULAHS LANE, IDAHO FALLS ID 83401
James P. Ahern	10 percent owner	20 WEST 64TH STREET, APT 18RS, NEW YORK NY 10023